An interventional study of Multimodal Rehabilitation Program in Parkinson Disease (PD), sponsored by Bilinç Doğruöz Karatekin. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Bilinç Doğruöz Karatekin · Not applicable, Interventional, and Treatment
This study aimed to investigate the relationship between instrumented balance measurements and clinical balance assessments in individuals with Parkinson's disease and to evaluate changes in balance and functional mobility following a 12-week multimodal rehabilitation program.
Eighteen individuals with Parkinson's disease participated in this prospective, single-group study. All participants received a rehabilitation program that included balance exercises, aerobic exercise, and balance training using the Korebalance system. The program was conducted twice weekly for 12 weeks.
Balance was assessed using the Korebalance system and the Berg Balance Scale (BBS). Functional mobility was evaluated using the Timed Up and Go (TUG) test. Assessments were performed before and after the rehabilitation program.
The study examined whether instrumented balance measurements were associated with clinical balance performance and whether balance and functional mobility changed following rehabilitation.
This prospective, single-center, single-group pre-post interventional study investigated instrumented balance assessment and changes in balance and functional mobility following multimodal rehabilitation in individuals with Parkinson's disease.
A total of 18 participants with Parkinson's disease were included. Eligible participants were adults aged 18 years or older with Hoehn and Yahr stages 1-3 who were able to participate in the rehabilitation program. Exclusion criteria included advanced Parkinson's disease (Hoehn and Yahr stages 4-5), significant cognitive impairment, other neurological disorders affecting balance, recent surgery within the preceding six months, and severe or uncontrolled systemic diseases that could interfere with participation.
All participants underwent a 12-week multimodal rehabilitation program consisting of two supervised sessions per week. The program included progressive static and dynamic balance exercises, functional mobility training, dual-task activities, moderate-intensity aerobic exercise, and balance training using the Korebalance system.
Balance training included tandem stance, single-leg stance when safely achievable, multidirectional weight shifting and stepping, repeated sit-to-stand exercises, obstacle negotiation, turning, and functional walking. More advanced activities included figure-of-eight walking, step negotiation, reactive postural control, and dual-task exercises combining motor and cognitive tasks. Aerobic training was performed using treadmill walking or stationary cycling at moderate intensity, generally corresponding to a Borg Rating of Perceived Exertion of 11-14.
The primary outcome measures were static and dynamic balance scores obtained using the Korebalance Premiere-19 system. Lower Korebalance scores indicated better balance performance.
Secondary outcome measures included the Berg Balance Scale (BBS), which assessed clinical balance, and the Timed Up and Go (TUG) test, which assessed functional mobility.
Outcome assessments were performed at baseline and after completion of the 12-week rehabilitation program.
Baseline instrumented balance measurements were examined in relation to clinical balance and functional mobility measures. Changes in instrumented balance, clinical balance, and functional mobility were evaluated by comparing measurements obtained before and after rehabilitation.
The study did not include randomization or a control group. All participants received the same multimodal rehabilitation intervention.
4,583 studies on the registry are indexed under Parkinson Disease; 1,097 are open to participants now.
This study's enrollment of 18 is below the median of 40 across 3,365 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →This is the only study on the registry with Bilinç Doğruöz Karatekin as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with Parkinson's disease received a 12-week supervised multimodal rehabilitation program, conducted twice weekly. The intervention included progressive balance exercises, functional mobility training, dual-task activities, moderate-intensity aerobic exercise, and Korebalance-assisted balance training. All participants received the same intervention, with no control group.
Behavioral: Multimodal Rehabilitation Program
Participants received a supervised multimodal rehabilitation program twice weekly for 12 weeks (24 sessions). The program included approximately 10 minutes of warm-up exercises, 20 minutes of progressive balance training, and 20 minutes of moderate-intensity aerobic exercise using a treadmill or stationary bicycle. Balance exercises included static and dynamic balance tasks, multidirectional stepping, functional mobility activities, turning, and dual-task training. Additional balance training was performed using the Korebalance Premiere-19 system. Exercise intensity was generally maintained at a Borg Rating of Perceived Exertion of 11-14. Exercises were individually progressed according to participant ability and safety.
Change in Static Korebalance Score
Static balance was assessed using the Korebalance Premiere-19 system. Measurements were obtained at baseline and after the 12-week multimodal rehabilitation program. Lower scores indicate better balance performance. Change was calculated as the post-intervention score minus the baseline score.
Time frame: Baseline and Week 12
Change in Dynamic Korebalance Score
Dynamic balance was assessed using the Korebalance Premiere-19 system. Measurements were obtained at baseline and after the 12-week multimodal rehabilitation program. Lower scores indicate better balance performance. Change was calculated as the post-intervention score minus the baseline score.
Time frame: Baseline and Week 12
Change in Berg Balance Scale Score
Clinical balance was assessed using the Berg Balance Scale (BBS), which consists of 14 items evaluating static and dynamic balance during functional activities. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 56. Higher scores indicate better balance performance. Change was calculated as the post-intervention score minus the baseline score.
Time frame: Baseline and Week 12
Change in Timed Up and Go Test Time
Functional mobility was assessed using the Timed Up and Go (TUG) test. Participants were instructed to stand up from a chair, walk 3 meters, turn around, return to the chair, and sit down. The time required to complete the test was recorded in seconds. Lower values indicate better functional mobility. Change was calculated as the post-intervention time minus the baseline time.
Time frame: Baseline and Week 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2024 to primary completion in Aug 2026, 30 months.
Of 1,296 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's 30 months is above that.
Counting every sponsor, half of 1,369 studies reached it within 24 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.